Morepen Laboratories reported a consolidated net profit of ₹563M for Q1FY26, a sharp increase compared to ₹114M in the same period last year. The pharmaceutical company's revenue from operations grew to ₹5.7B from ₹4.2B year-on-year, driven by higher sales volumes and improved operational efficiency. EBITDA surged to ₹825M from ₹242M, with EBITDA margin expanding significantly to 14.5% from 5.68%, reflecting strong operational leverage and cost discipline. This robust financial performance underscores the company's recovery trajectory and sustained demand for its product portfolio.

The Board of Directors approved the unaudited standalone and consolidated financial results during its meeting held on August 4, 2026. Statutory auditors S.P. Babuta & Associates conducted a limited review of the results in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company also set September 19, 2026, as the record date for determining shareholders eligible to receive the final dividend for FY26, subject to approval at the upcoming Annual General Meeting.

Financial Performance Highlights

The latest quarterly results reflect broad-based improvement across key financial metrics. Consolidated revenue from operations rose to ₹5,701.28 lakh in Q1FY26, compared to ₹4,252.39 lakh in the same period last year. Standalone revenue grew 38% to ₹5,410.41 lakh from ₹3,912.84 lakh. Profit before tax surged to ₹745.27 lakh (consolidated) from ₹155.16 lakh, reflecting effective cost management despite rising input costs. Earnings per share increased to ₹1.03 from ₹0.20 in Q1FY25.

Selling and distribution expenses increased to ₹533.14 lakh from ₹303.96 lakh, indicating aggressive market expansion efforts. Employee benefits expense rose to ₹624.44 lakh, up from ₹552.37 lakh, reflecting inflationary adjustments and hiring activities. Finance costs remained controlled at ₹48.41 lakh.

Key Board Resolutions

Beyond financial results, the Board approved several strategic initiatives requiring shareholder approval at the 41st AGM scheduled for September 26, 2026. These include the re-appointment of Mr. Sushil Suri as Chairman & Managing Director for a three-year term from October 20, 2026, to October 19, 2029. Suri, a Chartered Accountant with over 30 years in the pharmaceutical industry, succeeds himself following the completion of his previous tenure.

The Board also proposed extending the timeline for hiving off the Medical Devices Business into Morepen Medipath Limited (formerly Morepen Medtech Limited), a subsidiary, via slump sale. This material related-party transaction aims to streamline operations and focus core resources on pharmaceuticals. The AGM will be conducted through video conferencing or other audio-visual means, as permitted by Ministry of Corporate Affairs circulars.

What the Numbers Show

The disproportionate rise in net profit and EBITDA relative to revenue growth signals significant margin improvement. While revenue grew year-on-year, EBITDA nearly tripled and EBITDA margin expanded from 5.68% to 14.5%, indicating favorable product mix shifts or successful cost containment. The increase in selling and distribution expenses outpacing revenue growth warrants monitoring, as it may pressure margins if not accompanied by proportional sales gains in subsequent periods. The absence of exceptional items in Q1FY26 highlights that current profitability is operationally driven rather than reliant on one-off gains.

Morepen Laboratories has accepted the resignation of Mr. Bhola Prasad from the position of General Manager – Process Engineering & Technology Transfer, effective July 6, 2026. The company disclosed that the resignation was submitted due to personal reasons and the employee's intention to explore career growth outside the organization. Mr. Bhola Prasad was a functional head and classified as a Senior Management Personnel.

The disclosure was made to the stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing referenced the SEBI master circular regarding the disclosure of changes in senior management personnel. The resignation was submitted with immediate effect, and Mr. Bhola Prasad expressed his intention to ensure a smooth handover of responsibilities.

Details of Resignation

The following table outlines the particulars of the change in senior management personnel as disclosed in the regulatory filing:

The resignation letter addressed to The AVP – Operations (API) at Morepen Laboratories Ltd. in Baddi formally requested relief from the position of GM Tech transfer & process Engineering. Mr. Bhola Prasad acknowledged the opportunities received during his tenure and committed to assisting in the transition process.